I do agree that FDA was quite risk averse before especially in areas where the risk - reward would be better for terminally ill or other patients. Having said that this is a different kind of risk reward treatment where the patient might themselves like to try it even if the risks were elevated compared to other post Phase 3 solutions.

AFAIK critics pointed this to be a form of regulatory capture as well.